Herlinde Dumez

18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec®)

Sigrid Stroobants, J. Goeminne, M. Seegers et al. · European Journal of Cancer · 2003 · 526 citations

Oncologic Imaging, Medical Imaging, Imatinib Mesylate +10

Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants

Maria Dêbiec‐Rychter, Jan Cools, Herlinde Dumez et al. · Gastroenterology · 2005 · 492 citations · Full text

Pkc412 Inhibitor, Imatinib-resistant Mutants, Gastrointestinal Oncology +9

Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group

Maria Dêbiec‐Rychter, Herlinde Dumez, Ian Judson et al. · European Journal of Cancer · 2004 · 442 citations

Surgical Oncology, Bone Sarcoma Group, Gastrointestinal Oncology +8

Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3–pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial

Cora N. Sternberg, Iwona Skoneczna, J. Martijn Kerst et al. · The Lancet Oncology · 2014 · 381 citations

Radical Cystectomy, Urology, Surgical Oncology +7

Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes

Patrick Schöffski, Isabelle Laure Ray-Coquard, Angela Cioffi et al. · The Lancet Oncology · 2011 · 236 citations

Soft-tissue Sarcoma, Pathology, Phase 2 +2